Adoptive cell therapy (ACT) utilizing tumor-infiltrating lymphocytes (TILs) has significant potential in treating various cancers; however, its effectiveness is often compromised by the tendency of TILs to become exhausted and dysfunctional. Revitalizing these essential immune cells is crucial for amplifying their antitumor efficacy. Our study investigates the influence of spermidine on the metabolic pathways of TILs, focusing on its critical contribution to T cell vitality. We assessed the impact of spermidine on glucose absorption, mitochondrial functionality, and energy production in TILs. The application of spermidine resulted in a pronounced improvement in mitochondrial functionality and energy production, indicated by a surge in mitochondrial numbers and enhanced activity of the tricarboxylic acid (TCA) cycle. Importantly, the suppression of mitochondrial metabolism negated the beneficial effects of spermidine on mitigating exhaustion and enhancing cellular activity, highlighting the essential role of mitochondrial metabolism in the action of spermidine. Our research suggests that modulation of metabolism by spermidine could be a potential strategy to strengthen the antitumor capabilities of TIL-based treatments, offering a promising method to better manage solid tumors.
{"title":"Spermidine Remodels the Mitochondrial Metabolism of Tumor-Infiltrating Lymphocytes.","authors":"Yizhe Sun, Hao Fu, Xinyu Li, Meng Wan, Hongchao Xiong, Chaoting Zhang","doi":"10.1155/jimr/7550012","DOIUrl":"10.1155/jimr/7550012","url":null,"abstract":"<p><p>Adoptive cell therapy (ACT) utilizing tumor-infiltrating lymphocytes (TILs) has significant potential in treating various cancers; however, its effectiveness is often compromised by the tendency of TILs to become exhausted and dysfunctional. Revitalizing these essential immune cells is crucial for amplifying their antitumor efficacy. Our study investigates the influence of spermidine on the metabolic pathways of TILs, focusing on its critical contribution to T cell vitality. We assessed the impact of spermidine on glucose absorption, mitochondrial functionality, and energy production in TILs. The application of spermidine resulted in a pronounced improvement in mitochondrial functionality and energy production, indicated by a surge in mitochondrial numbers and enhanced activity of the tricarboxylic acid (TCA) cycle. Importantly, the suppression of mitochondrial metabolism negated the beneficial effects of spermidine on mitigating exhaustion and enhancing cellular activity, highlighting the essential role of mitochondrial metabolism in the action of spermidine. Our research suggests that modulation of metabolism by spermidine could be a potential strategy to strengthen the antitumor capabilities of TIL-based treatments, offering a promising method to better manage solid tumors.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"7550012"},"PeriodicalIF":3.6,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12571991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145431437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-28eCollection Date: 2025-01-01DOI: 10.1155/jimr/6600076
K Fischer, O Horno, B Raposo, I Godinho, H Ribeiro, H Veiga-Fernandes, M Martínez-López
Diet-induced obesity is a growing global health concern linked to various immunological alterations. Dendritic cells (DCs) are major regulators of the balance between pro-inflammatory and tolerogenic immune responses. Conventional Type 1 DCs (cDC1) contribute to oral tolerance by affecting the generation of food specific regulatory T cells (Tregs). Nevertheless, whether obesity affects cDC1/Treg pathways and the generation of food tolerance remains poorly understood. Here, we investigated the spatio-temporal impact of a high-fat, high-sugar diet (HFHSD) on the enteric immune system. Enteric immune composition was primarily altered by diet and intestinal region, independently of the duration of the dietary regimen. Notably, the lamina propria of animals fed with high-caloric diet was enriched in cDC1 overtime. While diet did neither reprogramme cDC1 gut-homing markers, nor costimulatory molecules nor cytokines, it increased intestinal cDC1 levels, which correlated with increased Tregs during oral tolerance protocols. Our findings contribute to a better understanding of high-caloric diet and food intolerances, while revealing a remarkable plasticity of the intestinal immune system in response to diet.
{"title":"High Fat and Sugar Diet Increases Enteric cDC1 and Oral Antigen-Specific Tregs.","authors":"K Fischer, O Horno, B Raposo, I Godinho, H Ribeiro, H Veiga-Fernandes, M Martínez-López","doi":"10.1155/jimr/6600076","DOIUrl":"10.1155/jimr/6600076","url":null,"abstract":"<p><p>Diet-induced obesity is a growing global health concern linked to various immunological alterations. Dendritic cells (DCs) are major regulators of the balance between pro-inflammatory and tolerogenic immune responses. Conventional Type 1 DCs (cDC1) contribute to oral tolerance by affecting the generation of food specific regulatory T cells (Tregs). Nevertheless, whether obesity affects cDC1/Treg pathways and the generation of food tolerance remains poorly understood. Here, we investigated the spatio-temporal impact of a high-fat, high-sugar diet (HFHSD) on the enteric immune system. Enteric immune composition was primarily altered by diet and intestinal region, independently of the duration of the dietary regimen. Notably, the lamina propria of animals fed with high-caloric diet was enriched in cDC1 overtime. While diet did neither reprogramme cDC1 gut-homing markers, nor costimulatory molecules nor cytokines, it increased intestinal cDC1 levels, which correlated with increased Tregs during oral tolerance protocols. Our findings contribute to a better understanding of high-caloric diet and food intolerances, while revealing a remarkable plasticity of the intestinal immune system in response to diet.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"6600076"},"PeriodicalIF":3.6,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12564431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145401121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liver disease impacts millions of Americans every year, which is compounded by the comorbidities and consequences that patients are susceptible to developing. Hepatic encephalopathy (HE) is a severe consequence of liver failure resulting in a range of cognitive deficits that heavily impact quality of life. Approximately 40% of acute liver failure (ALF) patients and 50% of chronic liver disease patients will be diagnosed with HE, and the associated prognosis is 44% and 42%, respectively. Though understanding of some of the neurologic impacts of liver impairment exists, the pathology of HE is not yet fully elucidated. Many in the field have come to appreciate the role of neuroinflammation in its pathogenesis. In this review, we have summarized recent studies investigating aspects of neuroinflammation such as microgliosis, astrogliosis, proinflammatory cytokine and chemokine production, and the involvement of the choroid plexus and meninges in HE.
{"title":"The Role of Neuroinflammation in the Pathogenesis of Hepatic Encephalopathy.","authors":"Kathryn Rhodes, Yubo Wang, Sharon DeMorrow, Poorani Gurumallesh","doi":"10.1155/jimr/6855563","DOIUrl":"10.1155/jimr/6855563","url":null,"abstract":"<p><p>Liver disease impacts millions of Americans every year, which is compounded by the comorbidities and consequences that patients are susceptible to developing. Hepatic encephalopathy (HE) is a severe consequence of liver failure resulting in a range of cognitive deficits that heavily impact quality of life. Approximately 40% of acute liver failure (ALF) patients and 50% of chronic liver disease patients will be diagnosed with HE, and the associated prognosis is 44% and 42%, respectively. Though understanding of some of the neurologic impacts of liver impairment exists, the pathology of HE is not yet fully elucidated. Many in the field have come to appreciate the role of neuroinflammation in its pathogenesis. In this review, we have summarized recent studies investigating aspects of neuroinflammation such as microgliosis, astrogliosis, proinflammatory cytokine and chemokine production, and the involvement of the choroid plexus and meninges in HE.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"6855563"},"PeriodicalIF":3.6,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12553031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145372718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-24eCollection Date: 2025-01-01DOI: 10.1155/jimr/3161910
Hana Grombirikova, Adam Markocsy, Anna Kocurkova, Jan Blatny, Marcela Vlkova, Peter Slanina, Eva Hlavackova, Veronika Fiamoli, Helena Schneiderova, Adam Klocperk, Dita Ricna, Eva Fronkova, Jan Kral, Anna Salingova, Milos Jesenak, Tomas Freiberger
X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection, and neoplasia (XMEN) is caused by a pathogenic variant in the magnesium transporter 1 (MAGT1) gene. The defect leads to impaired N-glycosylation which affects various immune processes. In this study, we described the disease course, clinical features and laboratory parameters observed in six patients from three families diagnosed with XMEN syndrome. They exhibit heterogeneous clinical manifestation while displaying typical laboratory signs of the disease, including decreased surface expression of NKG2D and CD28 on CD8+ T-cells and NK cells, as well as defects in the N-glycosylation of transferrin. We identified two novel variants in the cohort: a frameshift variant c.444dup in exon 3, and a splicing variant c.998-20_1008del. Notably, a patient with the c.444dup variant presented with severe autoimmune cytopenia as an isolated manifestation of the disease, while his younger brother, carrying the same variant, exhibited predominantly mild skin infections. These findings illustrate varying degrees of severity in penetrance and highlight that some patients may exhibit only partial symptoms. Furthermore, our study confirmed defects in perforin expression in XMEN syndrome. We observed a significant reduction in perforin expression within CD8+ T-cells and NK cells which may lead to increased susceptibility to recurrent infections and autoimmune complications frequently observed in XMEN patients.
{"title":"Atypical Phenotype of Predominant Autoimmune Cytopenia and Impaired Perforin Expression in XMEN Syndrome.","authors":"Hana Grombirikova, Adam Markocsy, Anna Kocurkova, Jan Blatny, Marcela Vlkova, Peter Slanina, Eva Hlavackova, Veronika Fiamoli, Helena Schneiderova, Adam Klocperk, Dita Ricna, Eva Fronkova, Jan Kral, Anna Salingova, Milos Jesenak, Tomas Freiberger","doi":"10.1155/jimr/3161910","DOIUrl":"10.1155/jimr/3161910","url":null,"abstract":"<p><p>X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection, and neoplasia (XMEN) is caused by a pathogenic variant in the magnesium transporter 1 (<i>MAGT1</i>) gene. The defect leads to impaired N-glycosylation which affects various immune processes. In this study, we described the disease course, clinical features and laboratory parameters observed in six patients from three families diagnosed with XMEN syndrome. They exhibit heterogeneous clinical manifestation while displaying typical laboratory signs of the disease, including decreased surface expression of NKG2D and CD28 on CD8<sup>+</sup> T-cells and NK cells, as well as defects in the N-glycosylation of transferrin. We identified two novel variants in the cohort: a frameshift variant c.444dup in exon 3, and a splicing variant c.998-20_1008del. Notably, a patient with the c.444dup variant presented with severe autoimmune cytopenia as an isolated manifestation of the disease, while his younger brother, carrying the same variant, exhibited predominantly mild skin infections. These findings illustrate varying degrees of severity in penetrance and highlight that some patients may exhibit only partial symptoms. Furthermore, our study confirmed defects in perforin expression in XMEN syndrome. We observed a significant reduction in perforin expression within CD8<sup>+</sup> T-cells and NK cells which may lead to increased susceptibility to recurrent infections and autoimmune complications frequently observed in XMEN patients.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"3161910"},"PeriodicalIF":3.6,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12551146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145372783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-21eCollection Date: 2025-01-01DOI: 10.1155/jimr/8766021
Bahareh Ebrahimi, Hossein Kargar Jahromi, Nazanin Shafiei Jahromi, Mina Molayem
Introduction: More than 6 million deaths from the novel coronavirus, the Coronavirus disease 2019 (COVID-19) infection, have prompted the development of several prophylactic vaccines of COVID-19. This systematic review summarizes the ocular complications of various COVID-19 vaccinations, diseases diagnosed, treatment, and risk factors.
Methods: The search was done in PubMed, Web of Science (WOS), and Google Scholar databases. Manifestations were classified depending on the type of vaccines and the interval between vaccination and the onset of symptoms. Other data such as patients' age, gender, underlying diseases, and follow-up data were also extracted.
Results: Initially, 10,242 articles were identified and 76 articles were eligible that among them 107 cases were reported. Ocular complications were diagnosed more often in Pfizer-BioNTech COVID-19 vaccine and Oxford-AstraZeneca COVID-19 vaccine (AstraZeneca) recipients than in others.
Conclusion: This systematic review highlights a wide range of ocular complications reported after COVID-19 vaccination, the most common of which is uveitis. While most cases were mild and self-limiting, some involved reactivation of preexisting inflammatory diseases. These findings emphasize the importance of postvaccination ocular surveillance. This is particularly important in individuals with a history of ocular inflammation and suggests a potential immunological mechanism that requires further investigation.
导语:超过600万人死于新型冠状病毒病2019 (COVID-19)感染,促使了几种COVID-19预防性疫苗的开发。本系统综述总结了各种COVID-19疫苗接种、疾病诊断、治疗和危险因素的眼部并发症。方法:在PubMed、Web of Science (WOS)和谷歌Scholar数据库中进行检索。根据疫苗类型和接种疫苗与症状发作之间的间隔对表现进行分类。其他数据如患者的年龄、性别、基础疾病和随访数据也被提取。结果:初步筛选出10242篇文献,符合条件的文献76篇,其中报告病例107例。辉瑞- biontech COVID-19疫苗和牛津-阿斯利康COVID-19疫苗(阿斯利康)接种者的眼部并发症发生率高于其他人群。结论:本系统综述强调了COVID-19疫苗接种后报告的各种眼部并发症,其中最常见的是葡萄膜炎。虽然大多数病例是轻微和自限性的,但一些病例涉及先前存在的炎症性疾病的重新激活。这些发现强调了疫苗接种后眼部监测的重要性。这在有眼部炎症史的个体中尤为重要,并提示需要进一步研究的潜在免疫机制。
{"title":"A Systematic Review of Ocular Complications Following Different Types of Covid-19 Vaccines.","authors":"Bahareh Ebrahimi, Hossein Kargar Jahromi, Nazanin Shafiei Jahromi, Mina Molayem","doi":"10.1155/jimr/8766021","DOIUrl":"10.1155/jimr/8766021","url":null,"abstract":"<p><strong>Introduction: </strong>More than 6 million deaths from the novel coronavirus, the Coronavirus disease 2019 (COVID-19) infection, have prompted the development of several prophylactic vaccines of COVID-19. This systematic review summarizes the ocular complications of various COVID-19 vaccinations, diseases diagnosed, treatment, and risk factors.</p><p><strong>Methods: </strong>The search was done in PubMed, Web of Science (WOS), and Google Scholar databases. Manifestations were classified depending on the type of vaccines and the interval between vaccination and the onset of symptoms. Other data such as patients' age, gender, underlying diseases, and follow-up data were also extracted.</p><p><strong>Results: </strong>Initially, 10,242 articles were identified and 76 articles were eligible that among them 107 cases were reported. Ocular complications were diagnosed more often in Pfizer-BioNTech COVID-19 vaccine and Oxford-AstraZeneca COVID-19 vaccine (AstraZeneca) recipients than in others.</p><p><strong>Conclusion: </strong>This systematic review highlights a wide range of ocular complications reported after COVID-19 vaccination, the most common of which is uveitis. While most cases were mild and self-limiting, some involved reactivation of preexisting inflammatory diseases. These findings emphasize the importance of postvaccination ocular surveillance. This is particularly important in individuals with a history of ocular inflammation and suggests a potential immunological mechanism that requires further investigation.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"8766021"},"PeriodicalIF":3.6,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16eCollection Date: 2025-01-01DOI: 10.1155/jimr/9126083
Fahimeh Baghaei, Zahra Hemmat, Amir Taherkhani, Setareh Shojaei, Ali Teimoori
Background: The urokinase plasminogen activator receptor (uPAR) plays a crucial role in cancer development and progression, making it an attractive target for immunotherapeutic strategies. This study aimed to develop a multiepitope vaccine targeting uPAR by incorporating T cell epitopes and a toll-like receptor 4 (TLR4) agonist as an adjuvant.
Methods: Immunoinformatics approaches were employed to predict and select immunogenic epitopes from the uPAR protein sequence. The selected epitopes were assembled into a multiepitope vaccine construct, including a TLR4 agonist derived from Mycobacterium tuberculosis as an adjuvant. The vaccine candidate underwent comprehensive in silico analyses, including antigenicity, allergenicity, physicochemical properties, and structural modeling. Molecular docking and molecular dynamics (MD) simulations were performed to evaluate the vaccine's interaction with the TLR4 receptor and assess its structural stability. Also, vector design was performed using the SnapGene software, while immune response simulations were conducted with the C-ImmSim server.
Results: The multiepitope vaccine construct comprised five cytotoxic T lymphocyte (CTL) epitopes, five helper T lymphocyte (HTL) epitopes, and the TLR4 agonist adjuvant. The vaccine was predicted to be nonallergenic, antigenic, and soluble, with favorable physicochemical properties. Molecular docking analysis revealed a strong binding affinity between the vaccine and TLR4, with a docking score of -334.37kcal/mol. MD simulations demonstrated the structural stability and rigidity of the vaccine-TLR4 complex. The computational immune simulation predicted a strong vaccine response with lasting antibody production, robust cellular immunity, and immunological memory formation.
Conclusion: The proposed multiepitope vaccine construct, consisting of carefully selected uPAR epitopes and a potent adjuvant, exhibits promising characteristics for inducing a robust immune response against cancer cells expressing uPAR. The favorable in silico results warrant further experimental validation and preclinical studies to assess the vaccine's efficacy and potential as a cancer immunotherapeutic agent.
{"title":"Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy.","authors":"Fahimeh Baghaei, Zahra Hemmat, Amir Taherkhani, Setareh Shojaei, Ali Teimoori","doi":"10.1155/jimr/9126083","DOIUrl":"10.1155/jimr/9126083","url":null,"abstract":"<p><strong>Background: </strong>The urokinase plasminogen activator receptor (uPAR) plays a crucial role in cancer development and progression, making it an attractive target for immunotherapeutic strategies. This study aimed to develop a multiepitope vaccine targeting uPAR by incorporating T cell epitopes and a toll-like receptor 4 (TLR4) agonist as an adjuvant.</p><p><strong>Methods: </strong>Immunoinformatics approaches were employed to predict and select immunogenic epitopes from the uPAR protein sequence. The selected epitopes were assembled into a multiepitope vaccine construct, including a TLR4 agonist derived from <i>Mycobacterium tuberculosis</i> as an adjuvant. The vaccine candidate underwent comprehensive in silico analyses, including antigenicity, allergenicity, physicochemical properties, and structural modeling. Molecular docking and molecular dynamics (MD) simulations were performed to evaluate the vaccine's interaction with the TLR4 receptor and assess its structural stability. Also, vector design was performed using the SnapGene software, while immune response simulations were conducted with the C-ImmSim server.</p><p><strong>Results: </strong>The multiepitope vaccine construct comprised five cytotoxic T lymphocyte (CTL) epitopes, five helper T lymphocyte (HTL) epitopes, and the TLR4 agonist adjuvant. The vaccine was predicted to be nonallergenic, antigenic, and soluble, with favorable physicochemical properties. Molecular docking analysis revealed a strong binding affinity between the vaccine and TLR4, with a docking score of -334.37kcal/mol. MD simulations demonstrated the structural stability and rigidity of the vaccine-TLR4 complex. The computational immune simulation predicted a strong vaccine response with lasting antibody production, robust cellular immunity, and immunological memory formation.</p><p><strong>Conclusion: </strong>The proposed multiepitope vaccine construct, consisting of carefully selected uPAR epitopes and a potent adjuvant, exhibits promising characteristics for inducing a robust immune response against cancer cells expressing uPAR. The favorable in silico results warrant further experimental validation and preclinical studies to assess the vaccine's efficacy and potential as a cancer immunotherapeutic agent.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"9126083"},"PeriodicalIF":3.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-14eCollection Date: 2025-01-01DOI: 10.1155/jimr/5600731
Min Gao, Nenghan Zhang, Yumin Xia
Cutaneous lupus erythematosus (CLE), a common clinical manifestation of lupus erythematosus (LE), significantly compromises patients' quality of life and social functioning due to its relatively high prevalence. While the exact pathogenesis of CLE remains incompletely understood, accumulating evidence highlights the pivotal role of interferon (IFN) as a central mediator in disease initiation and progression. Stromal cells and infiltrating immune cells within CLE lesions demonstrate elevated expression of IFN-stimulated genes (ISGs), establishing a characteristic IFN signature. IFN orchestrates multiple pathological processes, including chemokine-mediated immune cell recruitment, cutaneous inflammation cascade, and tissue fibrosis. This review systematically examines the IFN-CLE axis through an integrated analysis of in vitro and in vivo experimental data. Emerging clinical trials reveal therapeutic promise in strategies targeting plasmacytoid dendritic cells (pDCs), neutralizing IFN signaling, or blocking downstream pathways. Given the current limitations in CLE management, IFN-focused strategies may offer innovative solutions to address unmet clinical needs through precision immunomodulation.
{"title":"Focus on Interferon Signature in Cutaneous Lupus Erythematosus: Novel Therapies From Better Understanding of the Pathogenesis.","authors":"Min Gao, Nenghan Zhang, Yumin Xia","doi":"10.1155/jimr/5600731","DOIUrl":"10.1155/jimr/5600731","url":null,"abstract":"<p><p>Cutaneous lupus erythematosus (CLE), a common clinical manifestation of lupus erythematosus (LE), significantly compromises patients' quality of life and social functioning due to its relatively high prevalence. While the exact pathogenesis of CLE remains incompletely understood, accumulating evidence highlights the pivotal role of interferon (IFN) as a central mediator in disease initiation and progression. Stromal cells and infiltrating immune cells within CLE lesions demonstrate elevated expression of IFN-stimulated genes (ISGs), establishing a characteristic IFN signature. IFN orchestrates multiple pathological processes, including chemokine-mediated immune cell recruitment, cutaneous inflammation cascade, and tissue fibrosis. This review systematically examines the IFN-CLE axis through an integrated analysis of in vitro and in vivo experimental data. Emerging clinical trials reveal therapeutic promise in strategies targeting plasmacytoid dendritic cells (pDCs), neutralizing IFN signaling, or blocking downstream pathways. Given the current limitations in CLE management, IFN-focused strategies may offer innovative solutions to address unmet clinical needs through precision immunomodulation.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"5600731"},"PeriodicalIF":3.6,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12519497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atherosclerosis (AS) is a disease characterized by the presence of lesions in the arterial intima throughout the circulatory system. Lipid metabolism disorders form the pathological basis of AS. Immune injury resulting from lipid deposition, which is regulated by various cytokines, significantly contributes to disease progression. Follicular helper T (Tfh) cells are essential in the humoral immune response. The abnormal expression of surface molecules and cytokines by Tfh cells may contribute to the onset and progression of AS. Additionally, an increase in the Tfh cell population contributes to the progression of AS and coronary artery disease (CAD). Therefore, the targeting of Tfh cells and their associated functional molecules could serve as a promising therapeutic strategy against AS. This review summarizes current insights into the role of Tfh cells in AS and highlights their potential as therapeutic targets.
{"title":"Follicular Helper T Cells: Potential Interventional Targets in Atherosclerosis.","authors":"Yuxuan Chen, Wenxin Wang, Xueli Xia, Xun Xu, Shengjun Wang, Poorani Gurumallesh","doi":"10.1155/jimr/9247816","DOIUrl":"10.1155/jimr/9247816","url":null,"abstract":"<p><p>Atherosclerosis (AS) is a disease characterized by the presence of lesions in the arterial intima throughout the circulatory system. Lipid metabolism disorders form the pathological basis of AS. Immune injury resulting from lipid deposition, which is regulated by various cytokines, significantly contributes to disease progression. Follicular helper T (Tfh) cells are essential in the humoral immune response. The abnormal expression of surface molecules and cytokines by Tfh cells may contribute to the onset and progression of AS. Additionally, an increase in the Tfh cell population contributes to the progression of AS and coronary artery disease (CAD). Therefore, the targeting of Tfh cells and their associated functional molecules could serve as a promising therapeutic strategy against AS. This review summarizes current insights into the role of Tfh cells in AS and highlights their potential as therapeutic targets.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"9247816"},"PeriodicalIF":3.6,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-10eCollection Date: 2025-01-01DOI: 10.1155/jimr/6626309
TingTing Cao, Ying Wang, Juan Zhang, Wei Song, WeiJie Dai, GuoZhong Ji, Poorani Gurumallesh
Ulcerative colitis (UC) is a chronic, recurrent inflammatory bowel disease (IBD). Leonurine is an active component in Leonurus japonicus, involved in several processes such as inflammation, oxidation, and other processes. This study found that symptoms of colitis induced by 3% dextran sulfate sodium (DSS) solution in C57BL/6 mice were significantly alleviated after administration of leonurine, in terms of reduced body weight, shortened colon length, disease activity index (DAI), and colonic pathological damage. The expression of the tight junction (TJ) protein claudin-1 and occludin markedly increased, the levels of tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) significantly decreased. Findings from transmission electron microscopy (TEM) and intestinal permeability assessment experiments indicated that leonurine ameliorates the intestinal barrier. Leonurine regulated the pancreatic secretion pathway, significantly reduced the expression levels of Cela2a and Cela3b, and clearly decreased the abundance of Rikenellaceae_RC9_gut_group, UBA1819, Enterococcus, and Oscillibacter. We proposed that leonurine may improve DSS-induced colitis by regulating the pancreatic secretion pathway, modulating the gut microbiota, and improving intestinal barrier, potentially becoming a candidate for the treatment of UC.
{"title":"Leonurine Alleviates DSS-Induced Colitis in Mice by Regulating Pancreatic Secretion Pathway and Gut Microbiota.","authors":"TingTing Cao, Ying Wang, Juan Zhang, Wei Song, WeiJie Dai, GuoZhong Ji, Poorani Gurumallesh","doi":"10.1155/jimr/6626309","DOIUrl":"10.1155/jimr/6626309","url":null,"abstract":"<p><p>Ulcerative colitis (UC) is a chronic, recurrent inflammatory bowel disease (IBD). Leonurine is an active component in <i>Leonurus japonicus</i>, involved in several processes such as inflammation, oxidation, and other processes. This study found that symptoms of colitis induced by 3% dextran sulfate sodium (DSS) solution in C57BL/6 mice were significantly alleviated after administration of leonurine, in terms of reduced body weight, shortened colon length, disease activity index (DAI), and colonic pathological damage. The expression of the tight junction (TJ) protein claudin-1 and occludin markedly increased, the levels of tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) significantly decreased. Findings from transmission electron microscopy (TEM) and intestinal permeability assessment experiments indicated that leonurine ameliorates the intestinal barrier. Leonurine regulated the pancreatic secretion pathway, significantly reduced the expression levels of <i>Cela2a</i> and <i>Cela3b</i>, and clearly decreased the abundance of Rikenellaceae_RC9_gut_group, UBA1819, <i>Enterococcus</i>, and <i>Oscillibacter</i>. We proposed that leonurine may improve DSS-induced colitis by regulating the pancreatic secretion pathway, modulating the gut microbiota, and improving intestinal barrier, potentially becoming a candidate for the treatment of UC.</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"6626309"},"PeriodicalIF":3.6,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12514016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-10eCollection Date: 2025-01-01DOI: 10.1155/jimr/9786427
[This corrects the article DOI: 10.1155/2021/8883962.].
[这更正了文章DOI: 10.1155/2021/8883962。]
{"title":"Correction to \"Luteolin Regulates the Differentiation of Regulatory T Cells and Activates IL-10-Dependent Macrophage Polarization against Acute Lung Injury\".","authors":"","doi":"10.1155/jimr/9786427","DOIUrl":"10.1155/jimr/9786427","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2021/8883962.].</p>","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2025 ","pages":"9786427"},"PeriodicalIF":3.6,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12512325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}